Neuroblastoma

Loretta MS Lau, The Children's Hospital at Westmead and University of Sydney, Sydney, New South Wale, Australia
Meredith S Irwin, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada

Published online: March 2011

DOI: 10.1002/9780470015902.a0006054.pub2

Neuroblastoma, the third most common childhood tumour, originates from the sympathetic nervous system. Neuroblastoma is well known for its diverse clinical behaviour, ranging from spontaneous regression or maturation to aggressive metastatic disease. Neuroblastoma biology is complex and heterogeneous. The identification of genetic changes (deoxyribonucleic acid (DNA) ploidy, MYCN amplification and aberrations of chromosome 1p, 11q and 17q) and clinical variables (e.g. age and stage) that are highly predictive of outcome has facilitated stratification of patients into prognostic subsets and delivery of risk-adapted therapies. However, the key events that govern neuroblastoma initiation, differentiation or progression remain elusive. To date, no single oncogene or tumour suppressor gene has been identified in the majority of neuroblastoma tumours. Furthermore, despite recent improvements with the addition of immunotherapy the survival for high-risk neuroblastoma patients remains low and will require identification of novel therapeutic targets. The ultimate goal is to provide individualised assessment and therapy based on both the genetic variables of the patient as well as the tumour.

Key Concepts:

  • Neuroblastoma has diverse clinical behaviour and heterogeneous biology.
  • Amplification of the MYCN gene in neuroblastoma is prototypic for recurrent amplification of a proto-oncogene in human cancers.
  • Both germline and somatic ALK mutations are present in neuroblastoma.
  • Specific genetic changes, such as MYCN amplification, or loss of heterozygosity of 1p or 11q are highly predictive of poor prognosis.
  • Neuroblastoma treatment involves risk-adapted therapy, where patients are stratified into risk groups based on both clinical variables and tumour biology and the goal of current treatment strategies is to use these prognostic factors to decrease the intensity of therapy delivered to low and intermediate risk patients.
  • The current International Neuroblastoma Risk Group (INRG) Staging System utilises age, disease stage, tumour histology, MYCN status, DNA ploidy, aberrations of chromosome 11p to assign pre-treatment risk groups.
  • DNA copy number alterations of primary tumours allow the identification of two subgroups: (1) whole chromosome gains that result in hyperdiploidy are usually present in favourable prognosis tumours and (2) segmental chromosomal aberrations (e.g. MYCN amplification) are usually associated with poor prognosis tumours.
  • Immunotherapy with anti-GD2 antibody and cytokines following stem cell transplant has led to the first major improvement in survival for patients with high-risk neuroblastoma in the past two decades.

Keywords: neuroblastoma; neoplasm; paediatric; risk group; genetics; MYCN; ALK; 1p; 11q; immunotherapy

Figure 1. MYCN amplification: FISH (fluouroscence in situ hybridisation) using a probe to MYCN (labelled with red fluorescence) demonstrates high levels of MYCN in the nuclei of tumour cells (nuclei are counterstained in blue). MYCN amplification is defined by INRG as greater than 10 copies per cell. Courtesy of Dr. Mary Shago, Cytogenetics Laboratory, Hospital for Sick Children, Toronto, Ontario.
close
 References
    Ambros PF, Ambros IM, Brodeur GM et al. (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer 100: 1471–1482.
    Asgharzadeh S, Pique-Regi R, Sposto R et al. (2006) Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. Journal of National Cancer Institute 98: 1193–1203.
    Attiyeh EF, London WB, Mosse YP et al. (2005) Chromosome 1p and 11q deletions and outcome in neuroblastoma. New England Journal of Medicine 353: 2243–2253.
    Bagatell R, Beck-Popovic M, London WB et al. (2009) Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. Journal of Clinical Oncology 27: 365–370.
    Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nature Review. Cancer 3: 203–216.
    book Brodeur GM and Maris JM (2006) "Neuroblastoma". In: Pizzo PA and Poplack DG (eds) Principals and Practice of Pediatric Oncology, pp. 933–970. Philadelphia: J B Lippincott Company.
    Brodeur GM, Minturn JE, Ho R et al. (2009) Trk receptor expression and inhibition in neuroblastomas. Clinical Cancer Research 15: 3244–3250.
    Brodeur GM, Pritchard J, Berthold F et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. Journal of Clinical Oncology 11: 1466–1477.
    Brodeur GM, Seeger RC, Schwab M, Varmus HE and Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124.
    Capasso M, Devoto M, Hou C et al. (2009) Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nature Genetics 41: 718–723.
    Caron H, van Sluis P, van Hoeve M et al. (1993) Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nature Genetics 4: 187–190.
    Carr-Wilkinson J, O'Toole K, Wood KM et al. (2010) High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clinical Cancer Research 16: 1108–1118.
    Casciano I, Mazzocco K, Boni L et al. (2002) Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death and Differentiation 9: 246–251.
    Chen L, Iraci N, Gherardi S et al. (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Research 70: 1377–1388.
    Chen Y, Takita J, Choi YL et al. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971–974.
    Cohn SL, Pearson AD, London WB et al. (2009) The international neuroblastoma risk group (INRG) classification system: an INRG task force report. Journal of Clinical Oncology 27: 289–297.
    Corvi R, Amler LC, Savelyeva L, Gehring M and Schwab M (1994) MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proceedings of the National Academy of Sciences of USA 91: 5523–5527.
    De Preter K, Vermeulen J, Brors B et al. (2010) Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clinical Cancer Research 16: 1532–1541.
    Diskin SJ, Hou C, Glessner JT et al. (2009) Copy number variation at 1q21.1 associated with neuroblastoma. Nature 459: 987–991.
    George RE, London WB, Cohn SL et al. (2005) Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. Journal of Clinical Oncology 23: 6466–6473.
    George RE, Sanda T, Hanna M et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975–978.
    Gustafson WC and Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 29: 1249–1259.
    Hansford LM, McKee AE, Zhang L et al. (2007) Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Research 67: 11234–11243.
    Holzel M, Huange S, Koster J et al. (2010) NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142(2): 218–229.
    Iyer R, Evans AE, Qi X et al. (2010) Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clinical Cancer Research 16: 1478–1485.
    Janoueix-Lerosey I, Lequin D, Brugieres L et al. (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967–970.
    Janoueix-Lerosey I, Schleiermacher G, Michels E et al. (2009) Overall genomic pattern is a predictor of outcome in neuroblastoma. Journal of Clinical Oncology 27: 1026–1033.
    Kushner BH, Kramer K, Modak S and Cheung NK (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. Journal of Clinical Oncology 24: 5271–5276.
    London WB, Frantz CN, Campbell LA et al. (2010) Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. Journal of Clinical Oncology 28: 3808–3815.
    Look AT, Hayes FA, Shuster JJ et al. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. Journal of Clinical Oncology 9: 581–591.
    Maris JM, Mosse YP, Bradfield JP et al. (2008) Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. New England Journal of Medicine 358: 2585–2593.
    Matthay KK, Quach A, Huberty J et al. (2009a) Iodine-131 – metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. Journal of Clinical Oncology 27: 1020–1025.
    Matthay KK, Reynolds CP, Seeger RC et al. (2009b) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. Journal of Clinical Oncology 27: 1007–1013.
    Matthay KK, Villablanca JG, Seeger RC et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. New England Journal of Medicine 341: 1165–1173.
    Moll UM and Slade N (2004) p63 and p73: roles in development and tumor formation. Molecular Cancer Research 2: 371–386.
    Monclair T, Brodeur GM, Ambros PF et al. (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of Clinical Oncology 27: 298–303.
    Monteiro J and Fodde R (2010) Cancer stemness and metastasis: therapeutic consequences and perspectives. European Journal of Cancer 46: 1198–1203.
    Morozova O, Vojvodic M, Grinshtein N et al. (2010) Systems-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clinical Cancer Research 16(18): 4572–4582.
    Mosse YP, Laudenslager M, Khazi D et al. (2004) Germline PHOX2B mutation in hereditary neuroblastoma. American Journal of Human Genetics 75: 727–730.
    Mosse YP, Laudenslager M, Longo L et al. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930–935.
    Muth D, Ghazaryan S, Eckerle I et al. (2010) Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Cancer Research 70: 3791–3802.
    Oberthuer A, Berthold F, Warnat P et al. (2006) Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of Clinical Oncology 24: 5070–5078.
    Passoni L, Longo L, Collini P et al. (2009) Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Research 69: 7338–7346.
    Plantaz D, Mohapatra G, Matthay KK et al. (1997) Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. American Journal of Pathology 150: 81–89.
    Schleiermacher G, Michon J, Huon I et al. (2007) Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. British Journal of Cancer 97: 238–246.
    Schulte JH, Marschall T, Martin M et al. (2010) Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Research.
    Slack AD, Chen Z, Ludwig AD, Hicks J and Shohet JM (2007) MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells. Cancer Research 67: 2448–2455.
    Smith KM, Datti A, Fujitani M et al. (2010) Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Molecular Medicine 2(9): 371–384.
    Trochet D, Bourdeaut F, Janoueix-Lerosey I et al. (2004) Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. American Journal of Human Genetics 74: 761–764.
    Valsesia-Wittmann S, Magdeleine M, Dupasquier S et al. (2004) Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6: 625–630.
    Villablanca JG, Krailo MD, Ames MM et al. (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). Journal of Clinical Oncology 24: 3423–3430.
    Vogan K, Bernstein M, Leclerc JM et al. (1993) Absence of p53 gene mutations in primary neuroblastomas. Cancer Research 53: 5269–5273.
    Weiss WA, Aldape K, Mohapatra G, Feuerstein BG and Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO Journal 16: 2985–2995.
    Wolter J, Angelini P and Irwin M (2010) p53 family: therapeutic targets in neuroblastoma. Future Oncology 6: 429–444.
    Yu A, Gilman AL, Ozkaynak MF et al. Children's Oncology Group (2010) Anti- with GMCSF IL2 and isotretinoin for neuroblastoma. New England Journal of Medicine 363(14): 1324–1334.
 Further Reading
    Maris JM (2010) Recent advances in neuroblastoma. New England Journal of Medicine 362(23): 2202–2211.
    Schleiermacher G, Janoueix-Lerosey I, Ribeiro A et al. (2010) Accumulation of segmental alterations determines progression in neuroblastoma. Journal of Clinical Oncology 28(19): 3122–3130.
    Vermeulen J, De Preter K, Naranjo A et al. (2010) Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology 10(7): 663–671.

Related Sub-Topics:

Neurobiology of Disease | Cell Biology of Cancer | Cancer Genetics
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Neuroblastoma
 
How to Cite close
Lau, Loretta MS, and Irwin, Meredith S(Mar 2011) Neuroblastoma. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0006054.pub2]